INTRODUCTION {#s1}
============

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease -i.e. \< 1% acute myeloblastic leukemia cases (AML)- with a historically dismal prognosis. Despite most BPDCN patients treated with different intensive chemotherapy regimens (e.g. CHOP, AML-type and acute lymphoblastic leukemia (ALL)-type regimens) achieve complete remission (CR), the great majority relapse early after CR, with further resistance to therapy and a fatal outcome. Of note, a significant percentage (≈30%) \[[@R1]-[@R3]\] of BPDCN relapses occur in the central nervous system (CNS), either as isolated CNS relapses or in the context of a systemic relapse. This is in line with the relatively high rate (≈10% of cases) \[[@R1]-[@R6]\] of overt CNS involvement (i.e. confirmed by cytology) observed at diagnosis in patients with leukemic variant of BPDCN presenting with neurological symptoms.

Although BPDCN prognosis is extremely poor, patients treated with ALL-type regimens that include CNS prophylaxis \[[@R1]-[@R3]\] and/or allogeneic hematopoietic stem cell transplantation (AHSCT) \[[@R7], [@R8]\] appear to show a better outcome. Altogether, these findings suggest that occult CNS involvement might be already present at diagnosis in a significant fraction of BPDCN patients, and could contribute to explain the relatively high number of CNS recurrences \[[@R9]\].

Here, we prospectively evaluated for the first time the presence of CNS involvement by next generation flow cytometry (NGF) in 13 consecutive BPDCN patients studied at diagnosis (*n* = 10) or at disease recurrence (*n* = 3). The impact of CNS involvement and CNS-directed therapy in patient outcome was further validated in a retrospective series of 23 additional BPDCN patients.

RESULTS AND DISCUSSION {#s2}
======================

At diagnosis, most prospectively analyzed patients showed skin lesions (n=10/13; 77%), peripheral blood (7/13; 54%) and/or bone marrow (9/13; 69%) involvement with normal neurological physical examination (n=13/13; 100%) and a good performance status (ECOG≤0/1: n=12/13; 92%) (Table [1](#T1){ref-type="table"}). Despite this, cerebrospinal fluid (CSF) samples positive for tumor plasmacytoid dendritic cells were found in 6/10 (60%) cases studied at diagnosis --median of 11 tumor cells/μl (range: 0.6--47), representing 82% of the total CSF cellularity (range: 68%-95%)- in association with ≥20% bone marrow (BM) infiltration by tumor cells (6/6 vs. 1/4 cases, respectively; *p*=.03). Except for the high rate of occult CNS involvement at diagnosis, prospectively analyzed here for the first time, the above described pattern of extranodal disease involvement has been previously reported as typical for BPDCN patients \[[@R2], [@R4], [@R5]\].

###### BPDCN patients included in the prospective cohort (n=13): Disease features at diagnosis and follow-up including patient outcome

  Patient code                                                                                                  Gender       Age              ECOG    Skin lesions   BM % of blast cells at diagnosis   PB % of blast cells at diagnosis   CSF involvement at diagnosis   N. of blast cells/μl detected by NGF in CSF   CC result in CSF^\#^   Systemic chemo-therapy      IT therapy at diagnosis   Response to chemo-therapy   Relapse    Site of relapse        Time (months) to relapse/progression   Positive CSF\*   Time from diagnosis to IT therapy (days)   Type of IT therapy       N. of IT doses for CSF clearance   CNS relapse/progression   AHSCT      Disease status   Current status   Cause of death   Overall survival (months)
  ------------------------------------------------------------------------------------------------------------- ------------ ---------------- ------- -------------- ---------------------------------- ---------------------------------- ------------------------------ --------------------------------------------- ---------------------- --------------------------- ------------------------- --------------------------- ---------- ---------------------- -------------------------------------- ---------------- ------------------------------------------ ------------------------ ---------------------------------- ------------------------- ---------- ---------------- ---------------- ---------------- ---------------------------
  **NO CSF involvement at diagnosis by NGF (n=4)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  \#3                                                                                                           M            60               1       Yes            29                                 4                                  **No**                         0                                             Negative               LAL-07FRAIL                 Yes                       CR                          No                                                                       No               2                                          TIT                      NA                                 No                        Yes        CR               Alive                             38
  \#6                                                                                                           F            57               0       Yes            0                                  0                                  **No**                         0                                             NE                     LAL-AR/2011                 Yes                       CR                          Yes        Cutaneous              7                                      No               6                                          TIT                      NA                                 No                        Yes        SD               Alive                             27
  \#9                                                                                                           M            67               0       Yes            0                                  0                                  **No**                         0                                             NE                     LAL-07FRAIL                 Yes                       CR                          No                                                                       No               29                                         TIT                      NA                                 No                        No         CR               Alive                             20
  \#11                                                                                                          M            73               0       Yes            2                                  0                                  **No**                         0                                             NE                     LAL-07FRAIL                 Yes                       CR                          No                                                                       No               14                                         TIT                      NA                                 No                        No         CR               Alive                             9
  Subtotal                                                                                                      3M/1F        64 (57-73)       0       4/4            1 (0-29)                           0 (0-4)                            **0/4**                        0                                             0/1                                                4/4                       4/4 CR                      1/4                                                                      0/4              10 (2-29)                                                           NA                                 0/4                       2/4        3/4 CR           4/4 Alive                         24 (9-38)
  **CSF involvement at diagnosis by NGF (n=6)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  \#1                                                                                                           M            11               NR      No             80                                 83                                 **Yes**                        5,1                                           NE                     LAL-AR/1993                 Yes                       CR                          No                                                                       Yes              11                                         TIT                      1                                  No                        No         CR               Alive                             48
  \#4                                                                                                           M            16               0       Yes            94                                 68                                 **Yes**                        0,6                                           Negative               LAL-AR/2003                 Yes                       CR                          Yes        Leptom                 5                                      Yes              2                                          TIT & Lip AraC           1                                  Yes                       Yes        CR               Alive                             34
  \#5                                                                                                           M            67               0       Yes            80                                 45                                 **Yes**                        2,2                                           Positive               LAL-AR/2011                 Yes                       CR                          No                                                                       Yes              3                                          TIT                      1                                  No                        No         CR               EXITUS           Sepsis           2
  \#10                                                                                                          M            71               1       Yes            88                                 0                                  **Yes**                        6,4                                           Negative               LAL-07FRAIL                 Yes                       CR                          No                                                                       Yes              5                                          TIT                      4                                  No                        No         CR               Alive                             15
  \#12                                                                                                          F            79               2       No             68                                 4                                  **Yes**                        46,6                                          NE                     LAL-07FRAIL                 Yes                       CR                          No                                                                       Yes              7                                          TIT & Lip AraC           1                                  No                        No         CR               Alive                             7
  \#13                                                                                                          M            66               0       Yes            74                                 28                                 **Yes**                        6,1                                           NE                     Hyper-CVAD                  Yes                       CR                          No                                                                       Yes              6                                          TIT                      1                                  No                        No         CR               Alive                             6
  Subtotal                                                                                                      5M/1F        67 (11-79)       0       4/6            80 (68-94)                         37 (0-83)                          **6/6**                        5.6 (0.6-46.6)                                1/3                                                6/6                       6/6 CR                      1/6                                                                      6/6              6 (2-11)                                                            1 (1-44)                           1/6                       1/6        6/6 CR           5/6 Alive                         11 (2-48)
  **CSF involvement at relapse/progression by NGF (not evaluated at diagnosis; n=3)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  \#2                                                                                                           M            58               0       Yes            0                                  0                                  **NE**                         46,3                                          NE                     No treatment\> CHOP at PD   No                        PD                                                            14                                     Yes              426                                        HD MTX/AraC & Lip AraC   NC                                 Yes                       No         PD               EXITUS           PD               19
  \#7                                                                                                           M            78               1       No             94                                 33                                 **NE**                         958,1                                         NE                     CYC & PRED                  No                        PD                                                            5                                      Yes              173                                        NA                       NA                                 Yes                       No         PD               EXITUS           PD               5
  \#8                                                                                                           M            75               0       Yes            0                                  0                                  **NE**                         4,5                                           Positive               FLUGAZA                     No                        SD                          Yes        BM, nodal and leptom   7                                      Yes              226                                        Lip AraC                 1                                  Yes                       No         SD               EXITUS           PD               7
  Subtotal                                                                                                      3M/0F        75               0       2/3            0                                  0                                  NE                             46.3                                          1/1                                                0/3                       0/3 CR                      1/1                               7                                      3/3              226                                                                                                    3/3                       0/3        0/3 CR           0/3 Alive                         7
  **Total n=13**                                                                                                **11M/2F**   **67 (11-79)**   **0**   **10/13**      **68 (0-94)**                      **4 (0-83)**                       **6/10**                       **6.1 (0.6-958.1)**                           **2/5**                                            **10/13**                 **10/13**                   **3/11**                          **7 (5-14)**                           **9/13**         **7 (2-426)**                                                       **1**                              **4/13**                  **3/13**   **9/13 CR**      **9/13 Alive**                    **15 (2-48)**
  **Patients that received IT prophylaxis/therapy at diagnosis: Prospective vs validation cohort comparison**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Prospective (n=10)                                                                                            8M/2F        67                       8/10           71                                 4                                  6/10                           5,6                                           1/4                    10 ALL-type                 10/10                     10/10 CR                    2/10       1/2 CNS                6                                      6/10             6                                                                                                      1/10                      3/10       9/10 CR          9/10 Alive                        18
  Validation (n=5)                                                                                              3M/2F        31                       2/5            73                                 0                                  2/2                            NE                                            2/2                    4/5 ALL-type                5/5                       5/5 CR                      2/5        2/2 NR                 9                                      2/5              ≤15                                                                                                    0/4                       2/5        3/5 CR           3/5 Alive                         22
  *P* value                                                                                                     NS           0.03                     NS             NS                                 NS                                 NS                                                                                                  NS                          NS                        NS                          NS                                NS                                     NS               0.01                                                                                                   NS                        NS         NS               NS                                NS

ECOG: Eastern cooperative oncology group performance status; BM: Bone marrow; PB: Peripheral blood; CSF: Cerebrospinal fluid; NGF: Next generation flow cytometry; CC: Conventional cytology; IT: Intrathecal; CNS: Central nervous system; AHSCT: Allogeneic hematopoietic stem cell transplantation; M: Male; F: Female; NE: Not evaluated; PD: Progressive disease; CYC & PRED: Cyclophosphamide and prednisone; PD: Progressive disease; CR: Complete remission; SD: Stable disease; Leptom: Leptomeningeal; TIT: Triple intrathecal therapy (methotrexate cytarabine and hydrocortisone); Lip: Liposomal; AraC: cytarabine; HD MTX: High dose methotrexate; NA: Not applicable; NC: No clearance of CSF observed; ALL: Acute lymphoblastic leukemia; NR: Not reported; NS: Not statistically significant. \#Due to the confirmed superiority of NGF versus CC in detecting occult leptomeningeal disease\[[@R12]\], and the limited volume of available CSF sample, CC evaluation was not systematically performed in parallel \*At any time (diagnosis or follow-up).

Patients were grouped according to their CSF status at diagnosis. Results in the summary groups are expressed as number of cases from all cases within the group (for categorical variables) or as median (for continuous variables) and minimum and maximum values.

All the patients had a normal neurological physical examination at diagnosis. 10 were screened for parenchymal involvement with a negative result in all these cases. All but case \#7 received IT treatment at some point of the disease but none CNS radiotherapy.

"LAL-XXX" (NCT01358201, NCT00853008 and \[[@R21]\]) and Hyper-CVAD are ALL-type protocols, CHOP is a NHL-type protocol and FLUGAZA (NCT02319135) is an AML-type protocol. CYC & PRED is a palliative regimen.

Regarding the 3 patients referred at relapse (5, 7 and 14 months after diagnosis), none had been screened for CNS disease (nor received CNS therapy) at diagnosis; all 3 had their CSF referred because of the onset of neurological symptoms, consisting of seizure in two patients and the presence of symptoms and signs of intracranial hypertension together with involvement of cranial nerves in the remaining case. They all showed CNS involvement by NGF with \>50% tumor cells (958, 5 and 46 tumor cells/μl, respectively). These results confirm previous observations about the relatively high rate of overt CNS involvement in BPDCN, particularly at relapse \[[@R1]-[@R3]\]; in addition, these results also support the notion that many BPDCN patients may already have occult CNS disease at diagnosis, in the absence of neurological symptoms.

Despite BPDCN patients have been found to show already at diagnosis, a rather high rate (≈10%) \[[@R1]-[@R6]\] of CNS involvement by conventional CSF cytology (e.g. similar to ALL patients), they are neither routinely screened for CNS involvement, nor receive CNS-directed therapy. This is even more striking because CNS relapses have been recurrently reported among BPDCN patients at relapse at higher frequencies than at diagnosis (≈30%) \[[@R1]-[@R3]\]. Among other reasons, this might be due to the rarity of the disease --and hence the limited experience with these patients-, as well as the inclusion of BPDCN as a myeloid malignancy in the WHO classification \[[@R10]\], where CNS involvement at diagnosis is uncommon (\<5% of patients) \[[@R11]\] and therefore, systematic CSF screening is not performed at diagnosis, in the absence of neurological symptoms. Moreover, NGF has not been routinely applied for the diagnostic screening of CNS involvement in BPDCN patients, despite its higher sensitivity over conventional cytology for detecting tumor cells on stabilized CSF samples \[[@R12], [@R13]\], and the fact that NGF can detect CNS disease before clinical symptoms emerge \[[@R14]\].

Of note, follow-up CSF samples obtained after triple intrathecal therapy (TIT) showed absence of tumor cells in 6/6 CSF^+^ cases studied at diagnosis, either after one −5/6 cases (83%)- or 4 doses of therapy (6/6 cases; Table [1](#T1){ref-type="table"}). At the moment of closing this study, 5/6 cases remained CNS-disease free, in continuous CR; the remaining patient (case\#4 in Table [1](#T1){ref-type="table"}) had an isolated CNS relapse 6 months after diagnosis. Upon relapse, the patient received intrathecal (IT) chemotherapy, a single dose being sufficient to re-induce CR with NGF-negative CSF; subsequently, he underwent an AHSCT and remains disease-free for \>2 years. At the moment of closing this study, only 1/10 patients studied at diagnosis had died in CR (case \#5 in Table [1](#T1){ref-type="table"}), the other 9 patients remaining alive in CR after a median follow-up of 20 months (range: 6--48 months). In contrast, those three patients studied at disease recurrence suffered disease progression and death, despite IT therapy was administered in 2/3 cases (median overall survival (OS): 7 months) (Table [1](#T1){ref-type="table"}). Overall, these findings suggest that BPDCN patients with occult CNS involvement at diagnosis might specifically benefit from CNS-directed therapy, particularly if administered (early) at diagnosis; in line with this, early administration of TIT translated into a significantly better outcome and prolonged survival versus cases who did not receive CNS prophylaxis/therapy at diagnosis and presented with CNS-recurrent disease (Figure [1C and 1D](#F1){ref-type="fig"}).

![Prognostic impact of (occult) CSF involvement and administration of IT therapy at diagnosis in BPDCN patients\
CNS-RFS (panels A, C, E and G) and OS (panels B, D, F and H) curves are separately shown for the prospective cohort (panels A, B, C and D), the validation cohort (panels E and F) and the combined (prospective and validation) cohort (panels G and H).](oncotarget-07-10174-g001){#F1}

In order to further validate our results, a series of 23 BPDCN patients previously reported in the literature \[[@R1]\] -and recruited in an earlier time period-, was retrospectively analyzed; of note, no major differences were observed between the two cohorts (prospectively *vs*. retrospectively analyzed patients) in terms of disease features and outcome (Table [1](#T1){ref-type="table"}). Five of these 23 patients received IT prophylaxis at diagnosis and 4/23 received CNS-directed therapy at relapse/progression (Table [2](#T2){ref-type="table"}). In this independent validation cohort, patients who did receive IT prophylaxis at diagnosis also had prolonged CNS recurrence-free survival (CNS-RFS) (*p*=.06) and OS (*p*=.03) (Figure [1E and 1F](#F1){ref-type="fig"}). Univariate analysis of prognostic factors performed in the whole patient cohort (n=36) showed a favorable impact on CNS-RFS and/or OS for children (p\>.05; *p*=.03), patients receiving ALL-type therapy (*p*=.01; *p*=.002), AHSCT (*p*\>.05; *p*=.003) and IT prophylaxis/treatment at diagnosis (*p*=.002; *p*\<.001) (Figure [1G and 1H](#F1){ref-type="fig"}), the later variable emerging as the only independent (favorable) prognostic factor for CNS-RFS (p=.02, hazard ratio \[HR\]=11.2, 95% confidence interval \[CI\]: 1.4 -- 88.8) and OS (*p*=.001, HR=7.6, 95% CI: 2.2 -- 25.9).

###### BPDCN patients included in the validation cohort (n=23): Disease features at diagnosis and follow-up including patient outcome

  Patient code                                                 Gender   Age         Skin lesions   BM % of blast cells at diagnosis   PB % of blast cells at diagnosis   CSF involvement at diagnosis   Systemic chemotherapy-type regimen   Response to chemotherapy   Relapse   Site of relapse             Time (months) to relapse/progression   Positive CSF\*   Time from diagnosis to IT therapy (days)   CNS treatment          CNS relapse/progression   AHSCT   Current status   Cause of death        Overall survival (months)
  ------------------------------------------------------------ -------- ----------- -------------- ---------------------------------- ---------------------------------- ------------------------------ ------------------------------------ -------------------------- --------- --------------------------- -------------------------------------- ---------------- ------------------------------------------ ---------------------- ------------------------- ------- ---------------- --------------------- ---------------------------
  **NO CNS IT prophylaxis administered at diagnosis (n=18)**                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  \#4R                                                         M        63          No             58                                 8                                  **NE**                         AML-type                             CR                         Yes       CNS                         6                                      Yes              183                                        TIT                    Yes                       No      EXITUS           PD                    10
  \#6R                                                         M        76          Yes            0                                  0                                  **NE**                         NHL-type                             CR                         Yes       Skin                        5                                      No                                                                                 No                        No      EXITUS           PD                    13
  \#8R                                                         M        70          Yes            70                                 80                                 **NE**                         ALL-type                             CR                         Yes       CNS, BM                     8                                      Yes              244                                        TIT & radiotherapy     Yes                       No      EXITUS           PD                    14
  \#9R                                                         M        10          Yes            83                                 15                                 **NE**                         AML-type                             CR                         Yes       NR                          10                                     No                                                                                 NR                        No      EXITUS           PD                    11
  \#11R                                                        F        34          No             99                                 0                                  **NE**                         AML-type                             CR                         No                                                                           No                                                                                 No                        Yes     EXITUS           AHSCT complications   7
  \#19R                                                        M        81          Yes            98                                 0                                  **NE**                         NHL-type                             CR                         Yes       CNS, skin and lymph nodes   7                                      Yes                                                                                Yes                       No      EXITUS           PD                    8
  \#23R                                                        M        81          Yes            75                                 0                                  **NE**                         ALL-type                             ED                                                                                                      No                                                                                 No                        No      EXITUS           Sepsis                2
  \#29R                                                        M        78          No             65                                 35                                 **NE**                         AML-type                             ED                                                                                                      No                                                                                 No                        No      EXITUS           TreatTox              1
  \#31R                                                        M        64          Yes            82                                 66                                 **NE**                         NHL-type                             CR                         Yes       CNS, BM                     9                                      Yes              397                                        TIT & Liposomal AraC   Yes                       No      EXITUS           PD                    20
  \#33R                                                        M        72          Yes            81                                 0                                  **NE**                         NHL-type                             NR                                                               4                                      Yes                                                                                Yes                       No      EXITUS           PD                    4
  \#38R                                                        M        71          Yes            82                                 47                                 **NE**                         NHL-type                             ED                                                               3                                      No                                                                                 No                        No      EXITUS           PD                    3
  \#40R                                                        M        79          Yes            25                                 0                                  **NE**                         NHL-type                             CR                         Yes       NR                          22                                     No                                                                                 No                        No      EXITUS           PD                    22
  \#42R                                                        M        70          Yes            88                                 2                                  **NE**                         ALL-type                             ED                                                                                                      No                                                                                 No                        No      EXITUS           Sepsis                1
  \#58R                                                        F        54          Yes            60                                 40                                 **NE**                         AML-type                             ED                                                                                                      No                                                                                 No                        No      EXITUS           TreatTox              1
  \#59R                                                        M        46          Yes            90                                 10                                 **NE**                         NHL-type                             CR                         Yes       CNS                         5                                      Yes                                                                                Yes                       No      EXITUS           PD                    5
  \#61R                                                        M        52          No             58                                 12                                 **NE**                         AML-type                             CR                         No                                                                           No                                                                                 No                        Yes     Alive                                  71
  \#63R                                                        M        42          No             85                                 39                                 **NE**                         NHL-type                             CR                         Yes       CNS, BM                     8                                      Yes              230                                                               Yes                       No      EXITUS           PD                    30
  \#64R                                                        F        45          No             75                                 57                                 **NE**                         AML-type                             CR                         No                                                                           No                                                                                 No                        No      EXITUS           Sepsis                21
  Subtotal                                                     15M/3F   67(10-81)   12/18          78(0-99)                           11(0-80)                           **18 NE**                      3/18ALL-type                         12/18 CR                   9/12      6/9 CNS                     7(3-22)                                7/18             237(183-397)                                                      7/17                      2/18    1/18 Alive                             9(1-71)
  **CNS IT prophylaxis administered at diagnosis(n=5)**                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  \#12R                                                        F        31          No             45                                 0                                  **NE**                         ALL-type                             CR                         No                                                                           No               ≤15                                        TIT                    No                        Yes     Alive                                  153
  \#13R                                                        M        12          Yes            73                                 0                                  **NE**                         ALL-type                             CR                         No                                                                           No               ≤15                                        TIT                    No                        Yes     Alive                                  22
  \#28R                                                        M        53          Yes            76                                 0                                  **NE**                         ALL-type                             CR                         Yes       NR                          10                                     No               15                                         MTX & AraC             No                        No      EXITUS           PD                    14
  \#35R                                                        M        8           No             85                                 0                                  **Yes**                        ALL-type                             CR                         No                                                                           Yes              ≤15                                        MTX & Dex              No                        No      Alive                                  120
  \#44R                                                        F        47          No             73                                 69                                 **Yes**                        AML-type                             CR                         Yes       NR                          8                                      Yes              15                                         AraC                   NR                        No      EXITUS           PD                    10
  Subtotal                                                     3M/2F    31(8-53)    2/5            73(45-85)                          0(0-69)                            **2/2**                        4/5 ALL-type                         5/5 CR                     2/5                                   9(8-10)                                2/5              ≤15                                                               0/4                       2/5     3/5 Alive                              22(10-153)
  *P* value^\#^                                                NS       0.02        NS             NS                                 NS                                                                0.02                                 NS                         NS                                    NS                                     NS               0.007                                                             NS                        NS      0.02                                   0.03

BM: Bone marrow; PB: Peripheral blood; CSF: Cerebrospinal fluid; IT: Intrathecal; CNS: Central nervous Sytem; AHSCT: Allogeneic hematopoietic stem cell transplantation; M: Male; F: Female; NE: Not evaluated; ALL: Acute Lymphoblastic Leukemia; NHL: Non-Hodgkin Lymphoma; AML: Acute Myeloblastic Leukemia; CR: Complete remission; ED: Early death; SD: Stable disease; NR: Not reported; TIT: Triple intrathecal therapy (Methotrexate cytarabine and hydrocortisone); AraC: Cytarabine; MTX: Metothrexate; Dex: Dexamethasone; PD: Progressive disease; TreatTox: Treatment toxicity; NS: Not statistically significant.

Results in the summary groups are expressed as number of cases from all cases within the group or as median. \*At any time (diagnosis or follow-up) \#CNS IT prophylaxis administration at diagnosis versus not.

The high rate of CNS involvement found in our study strongly suggests that the CNS could be a persistent blast-cell sanctuary in BPDCN patients with leukemic presentation, due to the limited power of cytostatic drugs to cross the blood-brain barrier into the CSF and brain parenchyma \[[@R15]\]. This reservoir of leukemic cells may also contribute to BM/systemic disease recurrence. Longer survival rates observed in AHSCT BPDCN patients \[[@R7], [@R8]\], irrespective of IT medication administration, might be explained by the benefit of the antileukemic effect of donor allogeneic cells \[[@R16]\], able to circulate systemically and cross the blood-brain barrier. Unfortunately, AHSCT is not exempt from relapses (≈1/3 of patients) \[[@R7], [@R8]\], it cannot overcome the poor disease status beyond the first CR \[[@R7]\], and toxicity-related mortality is high \[[@R17]\]. Additionally, many patients are elderly or unfit subjects to undergo such an intensive therapeutic approach.

Recently, SL-401, a novel targeted therapy directed to the interleukin-3 receptor, has shown positive results on BPDCN patients with skin confined disease, whereas long-term benefit has not yet been observed in patients with the leukemic variant/phase of the disease \[[@R18]\]. No comparison can be established in terms of CNS relapses between both approaches (SL-401 *vs*. IT prophylaxis) since patients showing CNS involvement are excluded from the study (NCT02113982) and sites of relapse/progression after SL-401 administration have not been detailed \[[@R18], [@R19]\]. Nonetheless, evaluation of IT injection of this targeted therapy will be of great interest, particularly in CNS relapses.

To the best of our knowledge, this is the first study reporting a strikingly high frequency of occult CNS involvement at diagnosis in BPDCN patients, and the potential benefit of CNS-directed therapy to reverse the poor outcome of BPDCN patients,. Indirectly, our results also suggest that occult CNS disease might contribute to explain the higher frequency of recurrences (e.g. CNS) observed in these patients, despite their high CR rates. Further prospective studies on larger BPDCN patient cohorts studied at diagnosis are necessary to confirm our findings.

MATERIALS AND METHODS {#s3}
=====================

Ethics statement {#s3_1}
----------------

The study was approved by the Ethics Committee of the Cancer Research Center, and performed following the Declaration of Helsinki. Each participant gave his/her informed consent prior entering the study.

Patients and samples {#s3_2}
--------------------

Forty-one CSF samples from 13 consecutive BPDCN patients (11 males and 2 females; median age: 67 years, range: 11-79 years) were evaluated for the presence of CNS involvement by NGF. Cases were evaluated at diagnosis (*n* = 10) or at relapse/progression (*n* = 3) and subsequently, after IT therapy. Diagnosis of BPDCN was based on previously reported recommendations \[[@R10]\], including expression of markers claimed to be mandatory to allocate blast cells to the plasmacytoid dendritic cell lineage \[[@R20]\], by either flow cytometry or immunohistochemistry of peripheral blood specimens, BM samples or cutaneous lesions. The 10 patients studied at diagnosis received high-risk ALL-type treatment, based on the Spanish PETHEMA protocols (NCT01358201, NCT00853008 and \[[@R21]\])(*n* = 9) or HyperCVAD therapy (*n* = 1), including one dose of TIT as CNS prophylaxis at each treatment phase (Table [1](#T1){ref-type="table"}). For CSF-positive cases, additional IT treatment was given -TIT every 72h (*n* = 4) or liposomal cytarabine (50mg) every two weeks (*n* = 2)- until two consecutive CSF-negative samples were obtained. In turn, patients with recurrent disease (*n* = 3) received AML-type or NHL-type (CHOP) therapy (Table [1](#T1){ref-type="table"}).

In order to validate the impact of CNS involvement and CNS-directed therapy on patient outcome, an independent validation cohort of 23 BPDCN treated with ALL- (*n* = 7), AML- (*n* = 8) or NHL-type (*n* = 8) therapeutic regimens was retrospectively analyzed \[[@R1]\]. The intrathecal treatment administered to these patients is detailed in Table [2](#T2){ref-type="table"}.

Multiparameter NGF immunophenotypic studies were performed on Transfix™-stabilized CSF samples (Cytomark, Buckingham, UK) following the EuroFlow panels and protocols \[[@R12], [@R22]\]. Data analysis was performed with the Infinicyt software (Cytognos, Salamanca, Spain). The lower cut-off for CNS involvement was defined as a cluster ≥10 events with the appropriate phenotype, based on a 10-parameter tube (≥0.001 cells/μl).

Statistical analyses {#s3_3}
--------------------

The Mann-Whitney U (for continuous variables) and the χ^2^tests (for categorical variables) were used to determine the statistical significance of differences observed between groups (PASW 19 statistical software, IBM SPSS Statistics, IBM, Armonk, NY, USA). OS and CNS-RFS curves were plotted according to the method of Kaplan-Meier and compared using the (one-sided) log-rank test. Those variables showing prognostic value in the univariate analysis were also evaluated by multivariate analysis using a Cox stepwise regression model. Statistically significance was set at p values \< .05.
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